Company family · HQ CH
Ferring: medicine shortages
private
As of 2 Nov 2026, 27 Ferring products have a reported shortage across 10 countries, covering 7 medicines.
Products short27rank #80 of 464
Medicines7active ingredients
Countries10/16
New in 90 days5+1 vs market pace
Typical duration18 monthsmedian so far
Manufacturing43%demand-driven 29%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Long-run trend in Canada
Canada dashboardCanada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Desmopressin | 8 | 12 Mar 2021 | Manufacturing problem | 8/16 | |
| Human Menopausal Gonadotrophin | 8 | 20 Nov 2024 | Manufacturing problem | 5/16 | |
| Budesonide | 3 | 15 Jun 2021 | Increased demand | 5/16 | |
| Triptorelin | 3 | 8 Feb 2021 | Manufacturing problem | 3/16 | |
| Atosiban | 2 | 8 May 2026 | Increased demand | 5/16 | |
| Gonadorelin | 2 | 28 Mar 2017 | Other | 3/16 | |
| Mesalazine | 1 | 16 Oct 2026 | Manufacturing problem | 11/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.